Pneumococcal Vaccines

Katherine A. Poehling, MD, MPHPneumococcal Vaccines Work Group ChairAdvisory Committee on Immunization PracticesFebruary 22, 2023
Pneumococcal Vaccines Work Group

ACIP Members• Katherine Poehling (Chair)• Sarah Long Ex Officio Members• Jeffrey Kelman (CMS)• Lucia Lee (FDA)• Tina Mongeau (FDA)• Uzo Chukwuma (IHS)• Mamodikoe Makhene (NIH)CDC Lead• Miwako Kobayashi (NCIRD)

Liaison Representatives and • Lynn Fisher (AAFP

• Mark Sawyer (AAP/• Jason Goldman (ACP)• David Nace (AGS/• Aleksandra Wierzbowski • James McAuley (IDSA• William Schaffner (NFID• Virginia Caine (NMA• Monica Farley (VAM• Keith Klugman (BMG• Arthur Reingold (UC B• Lorry Rubin (CCM• Richard Zimmerman (U. of 
Pneumococcal Vaccines Work Group

CDC Contributors• Adam Cohen (Respiratory Diseases Branch)• Ryan Gierke (Respiratory Diseases Branch)• Jennifer Farrar (Respiratory Diseases Branch)• Pedro Moro (Immunization Safety Office)• Liz Velazquez (Immunization Services Division)• Marc Fischer (Arctic Investigations Program)

• Noele Nelson (Division of Bacterial Diseases)• Jessica MacNeil (ACIP Secretariat) GRADE/EtR consultants• Doug Campos-Outcalt• Rebecca Morgan
Pneumococcal vaccines currently recommend

use in the United States

Recommended for children

Recommeadults

Pneumococcal conjugate vaccinesPCV13PCV15PCV20Pneumococcal polysaccharide vaccinePPSV23 Risk-based 

recommendations

If previouPCV13 or 
All children under age 2 years have the same 

pneumococcal vaccine recommendations• 3 primary series and a booster=“3+1” schedule

PCV PCV PCV 

2 months 4 months 6 months 1

Primary Series 

Either PCV13 or PCV15 can be used for U.S. childre
Children with certain underlying conditions are reco

to receive PPSV23 in addition to the recommended 

Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on ImmunizatioPractices — United States, 2022 | MMWR (cdc.gov)

PPSV23

≥8 weeks

Recommended 

PCV doses PPSV23 

≥8 weeks ≥5 years

PPSV23

Recommended 

PCV doses

Note: Excludes catch-up vaccination schedules.CMC=chronic medical conditions, including chronic heart disease, chronic lung disease, diabetes mellitusCSF=cerebrospinal fluid 

Recommended 

PCV doses

Healthy 

children

CMC, CSF leak, 

cochlear 

implant

Immunocompromised

CMC aged 6–18 

years 
Approval of PCV20 use among Children Anticipated 

2022 2023

Pediatric PCV20 use approval 

anticipated Q2 2023

Pediatric PCV15 use approved

June 2022

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children | Pfizer

February 2023
Policy questions considered by the Work Gro

• Should PCV20 be recommended as an option for pneumo

conjugate vaccination according to currently recommendand schedules, for U.S. children aged <2 years

?

• Should PCV20 without PPSV23 be recommended as an op

pneumococcal vaccination for U.S. children aged 2–18 yeunderlying medical conditions that increase the risk of pneumococcal disease?
Today’s Pneumococcal Vaccines session outlin

Introduction Dr. Katherine P

(ACIP, WG Chai

Epidemiology of pneumococcal disease among U.S. children

Mr. Ryan Gierke (CDC/NCIRD)

Pediatric outpatient ARI visits and antibiotic use attributable to serotypes in higher valency PCVs

Ms. Laura King (U.C. Berkeley)

PCV20 phase 2/3 study results among children Dr. Wendy Wat

(Pfizer)

Preliminary EtR for PCV20 use in U.S. children Dr. Miwako Kob

(CDC/NCIRD)

Work Group considerations and next steps Dr. Miwako Kob

(CDC/NCIRD)